Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.

This study found that dutasteride may help prevent enteric neuronal damage in an animal model of Parkinson's disease, highlighting its potential for drug repurposing to address neuroinflammation.

This article discusses the potential mechanism by which 5α-reductase inhibitors might offer protection against SARS-CoV-2, emphasizing possible roles of dehydroepiandrosterone and its impact on nitric oxide bioavailability, but reports no new experimental results.

This study suggests that type I 5-alpha reductase may also play a role in hair growth, with dutasteride potentially being more potent than finasteride in modulating key hair growth gene expressions.

This review discusses plant-derived phytochemicals, such as phytosterols, polyphenols, and fatty acids, as potential alternatives to 5-alpha-reductase inhibitors for prostate cancer treatment, highlighting their promising anti-cancer properties and potentially fewer side effects compared to conventional drugs.

This study found that both finasteride and dutasteride led to morphological and functional kidney damage in rats, with more severe effects observed in the dutasteride group.

In this study, oral dutasteride treatment for at least 12 months was associated with either stabilization or improvement of male-pattern hair loss in the majority of patients.

This study found that testosterone promotes proliferation, migration, and invasion in human glioblastoma cell lines through its conversion into dihydrotestosterone, which can be inhibited by drugs blocking 5α-reductase activity.

This article discusses the approval status of 5α-reductase inhibitors for androgenetic alopecia, noting finasteride is FDA-approved for certain men while dutasteride is not approved in the US for this condition; it reports no new results.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

In this study, low dose finasteride or dutasteride treatment was found to reduce prostate specific antigen levels in men with androgenetic alopecia, though levels sometimes remained stable or increased in those with low baseline PSA.

This article discusses the characteristics of lichen planus pigmentosus and frontal fibrosing alopecia but reports no new clinical findings; the authors review existing knowledge.

This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.

This study reported a significant association between severe teenage acne and an increased risk of melanoma, potentially linked to androgen levels, though causation cannot be confirmed.

More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.

This review discusses chemoprevention for prostate cancer and suggests that further open and unbiased investigation into various preventive compounds, including 5α-reductase inhibitors, is needed.

This study found that dutasteride was more effective than finasteride in reducing total prostate volume and PSA levels and improving symptoms in patients with benign prostate hyperplasia.

This study suggests that dutasteride does not present a significant risk to wild fish populations at typical environmental concentrations, but its notable bioaccumulation requires further investigation.

This study concluded that both finasteride and dutasteride therapies significantly increased chromogranin A serum levels in men with benign prostatic hyperplasia, suggesting an activation of neuroendocrine differentiation.

This article reviews the Clinical Pearls presentation format introduced at the American College of Physicians' 2001 meeting for its effectiveness in applying practical clinical tips, but provides no new empirical results.

In this systematic review, dutasteride may be more effective than finasteride for hair growth in men with androgenetic alopecia, but the comparative magnitude of this effect is highly uncertain.

In this randomized trial of Iranian men with moderate to severe androgenetic alopecia, researchers found that both finasteride and dutasteride improved hair density over 24 weeks, with dutasteride showing stronger PSA reduction but similar safety to finasteride.

This review concluded that 5α-reductase inhibitors like finasteride and dutasteride offer limited additional feminising effects in hormone therapy for transfeminine individuals, with the clearest use being androgenetic alopecia treatment; more research is needed for other potential benefits.

This study reviews the use of natural products, like herbal extracts and essential oils, in treating male pattern baldness, noting their potential benefits compared to conventional therapies that may carry side effects or ethical concerns.

This research found that a novel dehydroepiandrosterone derivative (12) significantly reduces cell viability and increases apoptosis in testosterone-stimulated normal and tumor prostate cells, unlike finasteride and dutasteride, which also showed activity under dihydrotestosterone stimulation.

This source reports that in men treated with 5α-reductase inhibitors for androgenetic alopecia, sexual adverse events such as decreased libido and erectile dysfunction occurred at rates from 1.9% to 12% in clinical trials, with effects often being mild and reversible upon stopping treatment.

This study found that while 5α-reductase inhibitors like finasteride had many serious, unresolved adverse drug reactions, some were not listed in the existing product information.

This study used molecular docking simulations to identify approved drugs, including Bedaquiline and Telmisartan, with potential to treat Onchocerca volvulus infections by inhibiting key protein targets, suggesting these drugs could be repurposed for onchocerciasis treatment with further validation.

This review concludes that finasteride and dutasteride are the most evidence-supported oral treatments for androgenetic alopecia, with dutasteride offering slightly greater hair count improvements and both affected by genetic response modifiers.

This study reviews the effectiveness and safety of finasteride and dutasteride for treating androgenetic alopecia, highlighting that dutasteride reduces DHT more deeply than finasteride, with genetic factors influencing patient response and both drugs being evidence-supported options for men and women.